Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity

References

• Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986;4(8):1162–1170.
   PubMed Web of Science ®Google Scholar
• Lalami Y, Klastersky J. Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol. 2017;120:163–179.
   PubMed Web of Science ®Google Scholar
• Longo DL, Duffey PL, DeVita VT Jr., et al. The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol. 1991;9(11):2042–2051.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P, Moliterni A, et al., Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 332(14): 901–906. 1995. .
   PubMed Web of Science ®Google Scholar
• Lepage E, Gisselbrecht C, Haioun C, et al., Prognostic significance of received relative dose intensity in non-Hodgkin’s lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d’Etude des Lymphomes de l’Adulte). Ann Oncol. 4(8): 651–656. 1993.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21(24):4524–4531.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Friedberg J, et al., Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol. 22(21): 4302–4311. 2004.
   PubMed Web of Science ®Google Scholar
• Culakova E, Thota R, Poniewierski MS, et al. Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med. 2014;3(2):434–444.
   PubMed Web of Science ®Google Scholar
• Kawatkar AA, Farias AJ, Chao C, et al. Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population. Support Care Cancer. 2017;25(9):2787–2795.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Tomita D, et al. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. Breast Cancer Res Treat. 2013;139(3):863–872.
   PubMed Web of Science ®Google Scholar
• Repetto L. Investigators C. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey. Crit Rev Oncol Hematol. 2009;72(2):170–179.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Michels SL, Reynolds MW, et al. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010;116(23):5555–5563.
   PubMed Web of Science ®Google Scholar
• Weycker D, Barron R, Kartashov A, et al. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract. 2014;20(3):190–198.
   PubMed Web of Science ®Google Scholar
• Weycker D, Li X, Tzivelekis S, et al. Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Cancer. 2017;25(2):439–447.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al., Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 106(10): 2258–2266. 2006.
   PubMed Web of Science ®Google Scholar
• Tai E, Jr GPG, Dunbar A, et al. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract. 2017;13(6):e552–e561. .
   PubMed Web of Science ®Google Scholar
• Clark OA, Lyman GH, Castro AA, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23(18):4198–4214.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158–3167.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Culakova E, et al., The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 24(10): 2475–2484. 2013.
   PubMed Web of Science ®Google Scholar
• Mhaskar R, Clark OA, Lyman G, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Re. 2014(10):CD003039
   Google Scholar
• Hematopoietic growth factors: version 2. 2021. National Comprehensive Cancer Network; [updated 2021 Mar 23; cited 2021 May 12]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf
   Google Scholar
• Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199–3212.
   PubMed Web of Science ®Google Scholar
• D’Souza A, Jaiyesimi I, Trainor L, et al. Granulocyte colony-stimulating factor administration: adverse events. Transfus Med Rev. 2008;22(4):280–290. .
   PubMedGoogle Scholar
• Matikas A, Georgoulias V, Kotsakis A. Emerging agents for the prevention of treatment induced neutropenia in adult cancer patients. Expert Opin Emerg Drugs. 2016;21(2):157–166.
   PubMed Web of Science ®Google Scholar
• Shayne M, Crawford J, Dale DC, et al. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2006;100(3):255–262.
   PubMed Web of Science ®Google Scholar
• Culakova E, Poniewierski MS, Wolff DA, et al. The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study. SpringerPlus. 2015;4(1):396.
   PubMedGoogle Scholar
• Schwartzberg LS, Saleh M, Whittaker S, et al. Severe neutropenia and relative dose intensity among patients<65 and ≥65 years with non-hodgkin’s lymphoma receiving chop-based chemotherapy. Support Care Cancer. 2014;22(7):1833–1841.
   PubMed Web of Science ®Google Scholar
• Weycker D, Barron R, Edelsberg J, et al. Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. Breast Cancer Res Treat. 2012;133(1):301–310.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Crawford J, Tomita D, et al. Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2016;57(2):283–290. .
   PubMed Web of Science ®Google Scholar
• Citron ML. Dose-dense chemotherapy: principles, clinical results and future perspectives. Breast Care (Basel). 2008;3(4):251–255.
   PubMed Web of Science ®Google Scholar
• Gray R, Bradley R, Braybrooke J, Early Breast Cancer Trialists’ Collaborative Group. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019;393(10179):1440–1452. .
   PubMed Web of Science ®Google Scholar
• Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994;330(18):1253–1259.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014;32(18):1889–1894.
   PubMed Web of Science ®Google Scholar
• Culine S, Gravis G, Flechon A, et al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle invasive urothelial bladder cancer (MIUBC): preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses. J Clin Oncol. 2020;38(6_suppl):437.
   Web of Science ®Google Scholar
• Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014;32(18):1895–1901.
   PubMed Web of Science ®Google Scholar
• Havrilesky LJ, Reiner M, Morrow PK, et al. A review of relative dose intensity and survival in patients with metastatic solid tumors. Crit Rev Oncol Hematol. 2015;93(3):203–210.
   PubMed Web of Science ®Google Scholar
• Anuradha S, Donovan PJ, Webb PM, et al. Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study. Acta Oncol. 2016;55(2):226–233.
   PubMed Web of Science ®Google Scholar
• Fauci JM, Whitworth JM, Schneider KE, et al. Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer. Gynecol Oncol. 2011;122(3):532–535.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Moliterni A, Zambetti M, et al. 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005;330(7485):217.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Outcomes of early-stage breast cancer patients treated with sequential anthracyclines-taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial. Clin Transl Oncol. 2019;21(2):239–245.
   PubMed Web of Science ®Google Scholar
• Cespedes Feliciano EM, Chen WY, Lee V, et al. Body composition, adherence to anthracycline and taxane-based chemotherapy, and survival after nonmetastatic breast cancer. JAMA Oncol. 2020;6(2):264–270.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yu Q, Wu XC, et al. Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative. Breast Cancer Res Treat. 2018;169(1):175–187.
   PubMed Web of Science ®Google Scholar
• Aspinall SL, Good CB, Zhao X, et al. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. BMC Cancer. 2015;15:62.
   PubMed Web of Science ®Google Scholar
• Van Eeghen EE, Bakker SD, van Bochove A, et al. High risk stage 2 and stage 3 colon cancer, predictors of recurrence and effect of adjuvant therapy in a nonselected population. Int Sch Res Notices. 2015;2015:790186.
   PubMedGoogle Scholar
• Yabusaki N, Fujii T, Yamada S, et al. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma—including the analysis of clinicopathological factors influencing relative dose intensity. Medicine (Baltimore). 2016;95(29):e4282.
   PubMed Web of Science ®Google Scholar
• Hirakawa T, Yamaguchi H, Yokose N, et al. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol. 2010;89(9):897–904.
   PubMed Web of Science ®Google Scholar
• Lee S, Fujita K, Negoro E, et al. Impact of relative dose intensity of standard regimens on survival in elderly patients aged 80 years and older with diffuse large B-cell lymphoma. Haematologica. 2020;105(8):e415–e418.
   PubMed Web of Science ®Google Scholar
• Dlugosz-Danecka M, Szmit S, Ogorka T, et al. The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients. Cancer Med. 2019;8(3):1103–1109.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Suzuki I, Saitou K, et al. Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP. J Cancer Res Clin Oncol. 2020;146(11):2995–3002.
   PubMed Web of Science ®Google Scholar
• Gutiérrez A, Bento L, Bautista-Gili AM, et al. Differential impact of relative dose-intensity reductions in diffuse large B-cell lymphoma treated with R-CHOP21 or R-CHOP14. PLoS One. 2015;10(4):e0123978.
   PubMed Web of Science ®Google Scholar
• Klasa RJ, Murray N, Coldman AJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol. 1991;9(3):499–508.
   PubMed Web of Science ®Google Scholar
• Ladwa R, Kalas T, Pathmanathan S, et al. Maintaining dose intensity of adjuvant chemotherapy in older patients with breast cancer. Clin Breast Cancer. 2018;18(5):e1181–e1187.
   PubMed Web of Science ®Google Scholar
• Schraa SJ, Frerichs KA, Agterof MJ, et al. Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice. Eur J Cancer. 2017;79:152–157.
   PubMed Web of Science ®Google Scholar
• Smoragiewicz M, Javaheri KR, Yin Y, et al. Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer. J Gastrointest Cancer. 2014;45(4):460–465.
   PubMedGoogle Scholar
• Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663–1671.
   PubMed Web of Science ®Google Scholar
• Shayne M, Culakova E, Poniewierski MS, et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer. 2007;110(7):1611–1620.
   PubMed Web of Science ®Google Scholar
• Raza S, Welch S, Younus J. Relative dose intensity delivered to patients with early breast cancer: canadian experience. Curr Oncol. 2009;16(6):8–12.
   PubMed Web of Science ®Google Scholar
• Li S, Liu J, Guo H, et al. Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995-2015. Support Care Cancer. 2020;28(6):2637–2649.
   PubMed Web of Science ®Google Scholar
• Older adult oncology: verson 1. 2020 February 7. National Comprehensive Cancer Network; [ updated 2020 Nov 10; cited 2020 Jan 5]. Available from: https://www.nccn.org/about/news/ebulletin/ebulletindetail.aspx?ebulletinid=1578
   Google Scholar
• Denduluri N, Patt DA, Wang Y, et al. Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices. J National Compr Cancer Network. 2015;13(11):1383.
   PubMed Web of Science ®Google Scholar
• Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012;30(13):1553–1561.
   PubMed Web of Science ®Google Scholar
• Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165(11):1267–1273.
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Catalano PJ, Haller DG, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003;98(3):484–495.
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol. 2008;26(25):4109–4115.
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol. 2004;22(4):648–657.
   PubMed Web of Science ®Google Scholar
• Poikonen P. Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area. Acta Oncol. 2001;40(1):67–71.
   PubMed Web of Science ®Google Scholar
• Aapro M, Boccia R, Leonard R, et al. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer. 2017;25(11):3295–3304.
   PubMed Web of Science ®Google Scholar
• Awad M, Singh P, Zarxio HO. filgrastim-sndz): the first biosimilar approved by the FDA. P T. 2017;42(1):19–23.
   PubMedGoogle Scholar
• Drug approval package: neulasta (pegfilgrastim) injection [Internet]: US Food & Drug Administration; 2002 [ updated Jan 2002; cited 2020 Nov 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/125031_0000_NeulastaTOC.cfm
   Google Scholar
• Biosimilar and Interchangeable Biologics: more treatment choices [Internet]: US Food and Drug Administration; 2020 [ updated 2020 Mar 23; cited 2021 May 18]. Available from: https://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices
   Google Scholar
• Agboola F, Reddy P. Conversion from Filgrastim to Tbo-filgrastim: experience of a Large Health Care System. J Manag Care Spec Pharm. 2017;23(12):1214–1218.
   PubMed Web of Science ®Google Scholar
• Neupogen (filgrastim) prescribing information [Internet]. Thousand Oaks, CA: Amgen. 2018. updated Jun 2018; cited 2020 Oct 15]. Available from: https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/neupogen/neupogen_pi_hcp_english.pdf
   Google Scholar
• Granix (tbo-filgrastim) prescribing information [Internet] North Wales, PA: cephalon; 2019 [ updated Nov 2019; cited 2020 Oct 15]. Available from: https://www.granixhcp.com/globalassets/granix-hcp/prescribing-information.pdf
   Google Scholar
• Weycker D, Bensink M, Lonshteyn A, et al. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015. Curr Med Res Opin. 2017;33(12):2107–2113.
   PubMed Web of Science ®Google Scholar
• Weycker D, Li X, Figueredo J, et al. Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter? Support Care Cancer. 2016;24(5):2309–2316.
   PubMed Web of Science ®Google Scholar
• Papakonstantinou A, Hedayati E, Hellstrom M, et al. Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. Acta Oncol. 2020;59(1):75–81.
   PubMed Web of Science ®Google Scholar
• Wang L, Baser O, Kutikova L, et al. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2015;23(11):3131–3140.
   PubMed Web of Science ®Google Scholar
• Neulasta (pegfilgrastim) prescribing information [Internet]. Thousand Oaks, CA: Amgen; 2020;[ updated Jan 2020; cited 2020 Oct 15]. Available from: https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/neulasta/neulasta_pi_hcp_english.pdf
   Google Scholar
• Gawade PL, Li S, Henry D, et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer. 2020;28(9):4413–4424.
   PubMed Web of Science ®Google Scholar
• Dinan MA, Hirsch BR, Lyman GH. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. J Natl Compr Canc Netw. 2015;13(1):e1–7.
   PubMed Web of Science ®Google Scholar
• Trautman H, Szabo E, James E, et al. Patient-administered biologic and biosimilar filgrastim may offer more affordable options for patients with nonmyeloid malignancies receiving chemotherapy in the United States: a budget impact analysis from the payer perspective. J Manag Care Spec Pharm. 2019;25(1):94–101.
   PubMed Web of Science ®Google Scholar
• Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract. 2012;18(2):171–179.
   PubMedGoogle Scholar
• McBride A, Balu S, Campbell K, et al. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. Future Oncol. 2017;13(25):2285–2295.
   PubMed Web of Science ®Google Scholar
• McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ. 2017;20(10):1083–1093.
   PubMed Web of Science ®Google Scholar
• Aapro M, Ludwig H, Bokemeyer C, et al. Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study). Ann Oncol. 2016;27(11):2039–2045.
   PubMed Web of Science ®Google Scholar
• Gascón P, Aapro M, Ludwig H, et al. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). Support Care Cancer. 2016;24(2):911–925.
   PubMed Web of Science ®Google Scholar
• Eckstrom J, Bartels T, Abraham I, et al. A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI. Support Care Cancer. 2019;27(3):873–878.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Allcott K, Garcia J, et al. The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. Support Care Cancer. 2017;25(8):2619–2629.
   PubMed Web of Science ®Google Scholar
• Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother. 2006;40(3):402–407. .
   PubMed Web of Science ®Google Scholar
• Almenar Cubells D, Bosch Roig C, Jiménez Orozco E, et al. Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice. Eur J Cancer Care (Engl). 2013;22(3):400–412.
   PubMed Web of Science ®Google Scholar
• Almenar D, Mayans J, Juan O, et al. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study. Eur J Cancer Care (Engl). 2009;18(3):280–286.
   PubMed Web of Science ®Google Scholar
• Naeim A, Henk HJ, Becker L, et al. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer. 2013;13:11.
   PubMed Web of Science ®Google Scholar
• Cobb PW, Moon YW, Mezei K, et al. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): a phase 3 study. Cancer Med. 2020;9(17):6234–6243.
   PubMed Web of Science ®Google Scholar
• Barrett JA, Choi J, Lakshmikanthan S, et al. Eflapegrastim’s enhancement of efficacy compared with pegfilgrastim in neutropenic rats supports potential for same-day dosing. Experimental Hematology. 2020;92:51–61.
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Bhat G, Peguero J, et al. Eflapegrastim, a long-acting granulocyte-colony stimulating factor for the management of chemotherapy-induced neutropenia: results of a phase III trial. Oncologist 2020;25. doi:https://doi.org/10.1634/theoncologist.2020-0105.
   Google Scholar
• Schwartzberg LS, Bhat G, Restrepo A, et al. Pooled efficacy analysis from two phase 3 studies in patients receiving eflapegrastim, a novel, long-acting granulocyte-colony stimulating factor, following TC for early-stage breast cancer. Poster Presented at the Virtual San Antonio Breast Cancer Symposium. 2020; Abstract PS9–59.
   Google Scholar
• Clinicaltrials.gov. 2020. cited 2020 Dec 12]. Available from: https://clinicaltrials.gov/
   Google Scholar
• Xu F, Zhang Y, Miao Z, et al. Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial. Ann Transl Med. 2019;7(18):482. .
   PubMed Web of Science ®Google Scholar
• Zhou C, Huang Y, Wang D, et al. A randomized multicenter phase iii study of single administration of mecapegfilgrastim (HHPG-19K), a pegfilgrastim biosimilar, for prophylaxis of chemotherapy-induced neutropenia in patients with advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2016;17(2):119–127.
   PubMed Web of Science ®Google Scholar
• Tirelli U, Carbone A, Di Francia R, et al. A new peg-filgrastim biosimilar, mecapegfilgrastim for primary prophylaxis of chemotherapy-related neutropenia is now available. Ann Transl Med. 2020;8(5):166.
   PubMed Web of Science ®Google Scholar
• Kim GM, Kim JH, Kim JH, et al. A phase II study to evaluate the safety and efficacy of pegteograstim in Korean breast cancer patients receiving dose-dense doxorubicin/cyclophosphamide. Cancer Res Treat. 2019;51(2):812–818.
   PubMed Web of Science ®Google Scholar
• Lee KH, Kim JY, Lee MH, et al. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09. Support Care Cancer. 2016;24(4):1709–1717.
   PubMed Web of Science ®Google Scholar
• Pegteograstim biological approved in South Korea [Internet]: 2014. updated September 19, 2014; cited 2020 Nov 19]. Available from:. http://www.gabionline.net/Biosimilars/News/Pegteograstim-biological-approved-in-South-Korea
   Google Scholar
• Evive Biotech meets primary and secondary endpoints in global phase III clinical trial for their novel chemotherapy-induced neutropenia treatment [Internet]: Evive Biotech; 2020 [ updated 2020 Jul 7; cited 2020 Dec 14]. Available from: https://www.evivebiotech.com/press_releases/evive-biotech-meets-primary-and-secondary-endpoints-in-global-phase-iii-clinical-trial-for-their-novel-chemotherapy-induced-neutropenia-treatment/
   Google Scholar
• Glaspy J, Tang T, Rutty D, et al. A phase III, randomized, multi-centre, double-blind, placebo-controlled clinical trial of F-627 in women with breast cancer receiving myelotoxic chemotherapy. 2018 San Antonio Breast Cancer Symposium; December 4–8, 2018 2018: abstract P6-13–03. San Antonio, TX.
   Google Scholar
• Nicholson B, Lloyd GK, Miller BR, et al. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006;17(1):25–31.
   PubMed Web of Science ®Google Scholar
• Kashyap AS, Fernandez-Rodriguez L, Zhao Y, et al. GEF-H1 signaling upon microtubule destabilization is required for dendritic cell activation and specific anti-tumor responses. Cell Rep. 2019;28(13):3367–3380 e8.
   PubMed Web of Science ®Google Scholar
• Singh AV, Bandi M, Raje N, et al. A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. Blood. 2011;117(21):5692–5700.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang H, Gigant B, et al. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery. FEBS J. 2016;283(1):102–111.
   PubMed Web of Science ®Google Scholar
• Tonra JR, Lloyd GK, Mohanlal R, et al. Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies. Cancer Chemother Pharmacol. 2020;85(2):461–468.
   PubMed Web of Science ®Google Scholar
• Blayney DW, Zhang Q, Feng J, et al. Efficacy of plinabulin vs pegfilgrastim for prevention of chemotherapy-induced neutropenia in adults with non-small cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2020;6:e204429.
   PubMed Web of Science ®Google Scholar
• BeyondSpring announces positive topline results from its PROTECTIVE-2 phase 3 registrational trial of plinabulin in combination with pegfilgrastim for prevention of chemotherapy-induced neutropenia [Internet]: BeyondSpring; 2020 [ cited 2020 Dec 12]. Available from: https://www.beyondspringpharma.com/pressreleases/info.aspx?itemid=4239
   Google Scholar
• Blayney DW, Ginn G, Huang L, et al. Plinabulin and pegfilgrastim (Plin+Peg) versus peg monotherapy (Peg) after TAC: a comparison of efficacy, safety, relative dose intensity (RDI) and bone pain. Poster Presented at the Virtual San Antonio Breast Cancer Symposium 2020; Abstract PS11–15.
   Google Scholar
• Millward M, Mainwaring P, Mita A, et al. Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Invest New Drugs. 2012;30(3):1065–1073.
   PubMed Web of Science ®Google Scholar
• He S, Roberts PJ, Sorrentino JA, et al. Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Sci Transl Med. 2017;9:387.
   Web of Science ®Google Scholar
• Daniel D, Kuchava V, Bondarenko I, et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial. Int J Cancer. 2020. https://doi.org/10.1002/ijc.33453.
   Google Scholar
• Hart LL, Ferrarotto R, Andric ZG, et al. Myelopreservation with Trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. Adv Ther. 2021;38(1):350–365.
   PubMed Web of Science ®Google Scholar
• Weiss JM, Csoszi T, Maglakelidze M, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019;30(10):1613–1621.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J, Wright G, Thummala A, et al. Trilaciclib improves overall survival when given with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: final analysis of a randomized phase 2 trial. Presented at the 2020 Virtual Meeting of the San Antonio Breast Cancer Symposium December 8-11, 2020 Abstract PD1–06.
   Google Scholar
• Tan AR, Wright GS, Thummala AR, et al. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2019;20(11):1587–1601.
   PubMed Web of Science ®Google Scholar
• Weiss J, Goldschmidt J, Zoran A, et al. Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer. J Clin Oncol. 2020;38(15_suppl):12096.
   Web of Science ®Google Scholar
• FDA approves drug to reduce bone marrow suppression caused by chemotherapy [Internet]: U.S. Food & Drug Administration; 2021 [ updated 2021 Feb 12; cited 2021 May 10]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-drug-reduce-bone-marrow-suppression-caused-chemotherapy
   Google Scholar
• Pleimes D, Flechsig S, Meyer M. Effect of IEPA, a novel orally bioavailable small molecule, on chemotherapy-induced myelosuppression. Blood. 2014;124(21):4355.
   Web of Science ®Google Scholar
• Mayer F, Pleimes D, Schmidt M, et al. Investigation of the efficacy of imidazolyl ethanamide pentandioic acid (IEPA) to reduce chemotherapy-induced myelosuppression (CIM) in breast cancer patients. J Clin Oncol. 2019;37(15_suppl):e23098–e23098.
   Web of Science ®Google Scholar
• Pleimes D, Bunker V, Meyer M, et al. Effects of a novel orally bioavailable small molecule (imidazolyl ethanamide pentandioic acid) on acute radiation syndrome. Blood. 2018;132(Supplement 1):5089.
   Google Scholar
• Jeong J, Kim Y-J, Lee DY, et al. 1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) attenuates gemcitabine-induced neutrophil extravasation. Cell Biosci. 2019;9(1):4.
   PubMedGoogle Scholar
• Kim Y-J, Jeong J, Sohn K-Y, et al. Abstract 360: therapeutic potential of EC-18 as a chemotherapy adjuvant for 5-fluorouracil-induced neutropenia. Cancer Re. 2019;79(13 Supplement):360.
   PubMed Web of Science ®Google Scholar
• Kim S-B, Kim M-H. Abstract A070: a phase 1/2a, open-label, dose-escalation study of EC-18 in patients with metastatic breast cancer for the prevention of chemotherapy-induced neutropenia. Mol Cancer Ther. 2019;18(12 Supplement):A070.
   Web of Science ®Google Scholar
• Abboud CN, Akard LP, Andreadis C, et al. A randomized open label exploratory controlled trial of CLT-008 myeloid progenitor cells (MPC) to decrease infections during induction for AML. J Clin Oncol. 2018;36(15_suppl):7043.
   Google Scholar
• Griffiths EA, Alwan LM, Bachiashvili K, et al. Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic. J Natl Compr Canc Netw 2020 1–4 doi:https://doi.org/10.6004/jnccn.2020.7610
   PubMedGoogle Scholar
• Johnson P, Bancroft T, Barron R, et al. Discrete choice experiment to estimate breast cancer patients’ preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors. Value Health. 2014;17(4):380–389.
   PubMed Web of Science ®Google Scholar